

budesonide CFC-free inhaler 100 micrograms and 200 micrograms per actuation (Pulmicort®) (No: 536/09)

AstraZeneca UK Ltd

Product Update

06 February 2009 (*Issued March 2009*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

budesonide CFC-free inhaler (Pulmicort®) is accepted for use in NHS Scotland for the treatment of asthma.

Budesonide CFC-free inhaler (Pulmicort®) (hydrofluoroalkanes [HFA] pressurised metered dose inhaler [pMDI]) replaces the equivalent CFC-containing pMDI formulations at a similar cost per microgram.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 08 December 2008.

**Chairman
Scottish Medicines Consortium**